Epix Pharmaceuticals Inc. announced that results from a Phase IIa clinical trial of EP-2104R found that the imaging agent was able to detect blood clots not previously seen on MRI and enhanced images previously seen.
The data show EP-2104R was well-tolerated and able to detect or enhance clots on MRI images in all six of the body systems studied, Epix said. Blood clots are an underlying cause of several diseases, including deep vein thrombosis, pulmonary embolism, heart attack and stroke, and identifying a minimally invasive method for detecting clots would address a substantial medical need, Epix said.